COMP <GO>
TVTX vs DNTH // ALTMAN Z-SCORE & DEBT/EQUITY
Travere Therapeutics Inc. (NASDAQ) VS. Dianthus Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: TVTX 8
— DNTH 2
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: DNTH
LAST: $50.39 (-0.36%) • MKT CAP: $4.75B
balance-sheet
3.44
LAST: $82.38 (-0.39%) • MKT CAP: $4.61B
balance-sheet
26.00
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TVTX VS. DNTH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TVTX | DNTH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -13.00% | -30.70% | +17.70 | TVTX | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.33% | -2.79% | +3.12 | TVTX | /fcf-yield <GO> |
| Operating Margin | -12.80% | -60.00% | +47.20 | TVTX | /operating-margins <GO> |
| Net Profit Margin | -5.20% | -60.00% | +54.80 | TVTX | /net-margins <GO> |
| Revenue Growth (YoY) | 110.50% | -65.00% | +175.50 | TVTX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 3.44 | 26.00 | -22.56 | DNTH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 4/9 | +3.00 | TVTX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 35.8 | 46.8 | -11.00 | DNTH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 1.08 | 0.00 | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 18.0x | 20.0x | -2.00 | TVTX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.75B | $4.61B | $141.9M | TVTX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TVTX REV | DNTH REV | TVTX GROSS % | DNTH GROSS % | TVTX FCF | DNTH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $490.7M | $2.0M | 97.9% | — | $15.7M | -$129.2M |
| FY 2024 | $233.2M | $6.2M | 96.7% | — | -$248.0M | -$78.5M |
| FY 2023 | $145.2M | $2.8M | — | — | -$286.6M | -$37.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TVTX // BETA 1.08
DNTH // BETA 1.08